FDA approves first topical hyperhidrosis treatment

The FDA has approved glycopyrronium (Qbrexza™) cloth for the treatment of pediatric and adult patients with primary axillary hyperhidrosis. Glycopyrronium is the first FDA-approved, once-daily, topical prescription for hyperhidrosis, and is expected to be available in October. The cloth is applied directly to the skin of the underarms and is designed to block sweat production by inhibiting sweat gland activation.

According to the International Hyperhidrosis Society (IHHS), hyperhidrosis occurs in more than 3 percent of the world’s population — roughly 220 million people. Learn more as experts discuss current and new treatments for this condition in Dermatology World.

Article via: American Academy of Dermatology.

V. Heydendael